LOOK CLOSER TO SEE WHAT THALASSEMIA IS HIDING

It may not always be apparent, but serious risk of morbidities can exist in some patients regardless of transfusion history.^1,2

This site features real patients who have been compensated for their participation.

Emerging data show chronic anemia may be associated with serious long-term complications in NTD patients with thalassemia¹

While the focus over many years has been on patients with thalassemia who are dependent on transfusions for survival, new data reveal that chronic anemia may be associated with serious complications in non–transfusion-dependent (NTD) patients.^1-3

Explore the latest data

Want to receive more valuable info and support? Sign up

Thalassemia is a chronic genetic blood disorder^2,4

Thalassemia may be classified as either alpha-thalassemia or beta-thalassemia, depending on the affected genes. It’s a complex disease with various subtypes (ie, “thalassemia minor,” “thalassemia intermedia,” and “thalassemia major”) and classifications (ie, “non–transfusion-dependent” and “transfusion-dependent”); however, transfusion dependence may not adequately predict patient risk.^1,2,4

The pathophysiology of thalassemia shows that if left untreated in some, it can lead to progressive organ damage and serious and potentially irreversible morbidities.^5,6

See pathophysiology and complications

Patients, regardless of transfusion frequency, may be at risk for serious complications and need a long-term management plan.^1,5,7

For Healthcare Professionals

Stay up to date

Get the latest thalassemia information.

Required field*

First Name*

Last Name*

Email Address*

Your National Provider Identifier (NPI) number*Look up your NPI number

Specialty

Practice Setting

I'd like to schedule a meeting with an Agios representative

By clicking “SUBMIT”, I consent that the information I am providing may be used by Agios and its agents to keep me informed about disease state education, products, or other opportunities that may be of interest to me via e-mail. I understand and agree that the information I provide will be used in accordance with the Agios Privacy Policy, including to provide me with marketing information, offers, and promotions, and to contact me for my opinions regarding Agios products, programs, and services.*

References:

1. Musallam KM, Cappellini MD, Daar S, Taher AT. Morbidity-free survival and hemoglobin level in non-transfusion dependent beta-thalassemia: a 10-year cohort study. Ann Hematol. 2022;101(1):203-204. doi:10.1007/s00277-020-04370-2 2. Musallam KM, Taher AT, Cappellini MD, et al. Untreated anemia in nontransfusion-dependent β-thalassemia: time to sound the alarm. Hemasphere. 2022;6(12):e806. doi:10.1097/HS9.0000000000000806 3. Musallam KM, Vitrano A, Meloni A, et al. Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia. Am J Hematol. 2022;97(2):E78-E80. doi:10.1002/ajh.26428 4. What is thalassemia? Centers for Disease Control and Prevention. Accessed March 27, 2024. https://www.cdc.gov/ncbddd/thalassemia/facts.html 5. Taher AT, Musallam KM, Cappellini MD. Guidelines for the Management of Non-Transfusion-Dependent β-Thalassemia. 3rd ed. Nicosia, Cyprus: Thalassemia International Federation; 2023. 6. Taher AT, Musallam KM, Cappellini MD. ß-Thalassemias. N Engl J Med. 2021;384(8):727-743. doi:10.1056/NEJMra2021838 7. Farmakis D. Management of Transfusion Dependent Thalassaemia (TDT): A Short Guide. 2nd ed. (Eleftheriou A, ed.). Thalassaemia International Federation; 2022. https://thalassaemia.org.cy/publications/tif-publications/a-short-guide-for-the-management-of-transfusion-dependent-thalassaemia-2022/